Unitas Global Acquires INAP's Network Business Assets
9.5.2022 14:30:00 EEST | Business Wire | Press release
Unitas Global, a Digital Alpha portfolio company, announces today that it has acquired INAP’s Network Business assets, including INAP Japan, enhancing its portfolio of network service offerings that enable hybrid cloud environments. The combination of these two companies creates a high-growth next generation networking platform focused on simplifying the way customers buy network connectivity to enable the seamless movement of data between various cloud and on-premises environments.
The combination of the INAP network technologies, including its patented, intelligent routing software, Managed Internet Route Optimizer (MIRO), with Unitas Global's automated design and pricing platform, Unitas Nexus™, and its global network, Unitas Reach™, creates a compelling offer to meet the needs of enterprises modernizing their digital infrastructure. In addition, this acquisition provides Unitas Global with a significant expansion of over a thousand multinational enterprise customers as well as global network serving 18 markets with Performance IP™.
"We are thrilled to have completed the acquisition of INAP's Network Business and excited to welcome their customers, vendors and employees to the Unitas Global team," comments Patrick Shutt, CEO of Unitas Global. "The disruptive nature of Unitas' networking services strategy that enables hybrid cloud environments has become increasingly self-evident in the market. This acquisition is the next step to become the market leader redefining an agile hybrid cloud for the enterprise," comments Grant Kirkwood, CTO of Unitas Global.
An additional benefit of the transaction is the synergy of INAP becoming a strategic customer of Unitas Global. INAP will continue to offer high-performance connectivity services alongside its colocation and cloud solutions, further expanding its portfolio with Unitas Reach™ network transformation solutions, including the most recent alliance announcement with PacketFabric.
“The transaction is a true win-win for everyone involved. Unitas Global will continue to provide the high-quality services that customers enjoy today while investing in new solutions to enable further network transformation tomorrow," comments Mike Sicoli, CEO of INAP. "We also look forward to partnering with Unitas Global to bring an expanded portfolio of connectivity offerings to our colocation and cloud customers."
"The acquisition of INAP’s Network Business assets is a powerful proof point of Digital Alpha's commitment to investing in and developing transformative next generation networks that provide a more holistic networking-as-a-service solution in the currently fragmented marketplace," states Rick Shrotri Managing Partner of Digital Alpha Advisors.
For more information, visit: https://www.unitasglobal.com/
About Unitas Global
Unitas Global is a next-generation network service provider offering automated ubiquitous edge access to cloud everywhere. The combination of its Unitas Nexus™ platform and global Unitas Reach™ network provides the most transformative network environments that are easy to design, procure, and fully managed. Analyzing price and performance requirements in real-time makes Unitas Nexus™ one of the most advanced go-to-market platforms for MSPs, hyperscale cloud providers, and datacenter operators worldwide. Unitas Reach™ access, IP, and SDN provide cost-optimized network connectivity with the agility needed to scale quickly and support the growing demands of applications on network architectures, performance, and costs. Unitas Global is a Digital Alpha Advisors portfolio company. Learn more at unitasglobal.com or connect with Unitas at LinkedIn, Twitter, and its Blog.
About INAP
INAP is a global provider of performance-driven, secure hybrid infrastructure solutions, enabling technology leaders to simplify their cloud journeys and accelerate innovation. INAP's expansive suite of bare metal cloud, modern data center, optimized network and security solutions help businesses flexibly and reliably move workloads to the right destination at the right time to maximize the results of their IT strategy. For more information, visit www.inap.com
About Digital Alpha Advisors, LLC
Digital Alpha Advisors, LLC is an investment firm focused on digital infrastructure required by the rapidly expanding digital economy, with total assets under management of over $1.5B. The firm has a strategic collaboration agreement with Cisco Systems, Inc. and has partnered with other leading Silicon Valley firms. Digital Alpha believes it is the first firm focused on making private equity investments in the significant growth opportunities required to underpin the Digital Economy, including next generation communications networks, IoT platforms for urban infrastructure, and cloud-based data management platforms. Digital Alpha was founded in 2017 by Rick Shrotri, former Head of the Global Infrastructure Funds (GIF) team at Cisco, and closed its latest Fund – Digital Alpha Fund II, LP – in early 2021. For more information, please visit www.digitalalpha.net.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220508005058/en/
Contact information
Media Contacts for Unitas Global:
Ilissa Miller
iMiller Public Relations
Tel: +1.866.307.2510
Email: Unitasglobal@imillerpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom